WallStSmart

AstraZeneca PLC (AZN)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 283837% more annual revenue ($58.74B vs $20.69M). AZN leads profitability with a 17.4% profit margin vs 5.8%. ZJYL trades at a lower P/E of 11.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

ZJYL

Hold

36

out of 100

Grade: F

Growth: 2.7Profit: 4.5Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued

Intrinsic value data unavailable for ZJYL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

ZJYL2 strengths · Avg: 10.0/10
P/E RatioValuation
11.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Areas to Watch

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

ZJYL4 concerns · Avg: 2.8/10
Market CapQuality
$18.00M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.8%3/10

ROE of 4.8% — below average capital efficiency

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

Revenue GrowthGrowth
-16.5%2/10

Revenue declined 16.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bull Case : ZJYL

The strongest argument for ZJYL centers on P/E Ratio, Price/Book.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : ZJYL

The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.

Key Dynamics to Monitor

ZJYL carries more volatility with a beta of 9.37 — expect wider price swings.

AZN is growing revenue faster at 4.1% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (64/100 vs 36/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.

Want to dig deeper into these stocks?